+ cytotoxic T-lymphocyte (CTL) responses have been shown to be important in the control of human and simian immunodeficiency virus infections. Infection of sheep with visna/maedi virus (VISNA), a related lentivirus, induces specific CD8 + CTL in vivo, but the specific viral proteins recognized are not known. To determine which VISNA antigens were recognized by sheep CTL, we used recombinant vaccinia viruses expressing the different genes of VISNA: in six sheep (Finnish Landrace¾Dorset crosses, Friesland and Lleyn breeds) all VISNA proteins were recognized except TAT. Two sheep, shown to share major histocompatibility complex (MHC) class I alleles, recognized POL and were used to map the epitope. The pol gene is 3267 bp long encoding 1088 aa. By using recombinant vaccinia viruses a central portion (nt 1609-2176, aa 537-725) was found to contain the CTL epitope and this was mapped with synthetic peptides to a 25 aa region (aa 612-636). When smaller peptides were used, a cluster of epitopes was detected: at least three epitopes were present, at positions 612-623: DSRYAFEFMIRN; 620-631: MIRNWDEEVIKN; and 625-635: EEVIKNPIQAR. A DNA-prime-modified vaccinia virus Ankara (MVA)-boost strategy was employed to immunize four sheep shown to share MHC class I allele(s) with the sheep above. Specific CTL activity developed in all the immunized sheep within 3 weeks of the final MVA boost although half the sheep showed evidence of specific reactivity after the DNA-prime immunizations. This is the first report, to our knowledge, of induction of CTL by a DNA-prime-boost method in VISNA infection.
INTRODUCTION
Visna/maedi virus (VISNA) establishes a life-long infection of sheep, leading to progressive inflammatory disease in multiple organs, e.g. interstitial pneumonitis, meningoencephalomyelitis, mastitis and arthritis (Narayan & Clements, 1989) . VISNA is a member of the subfamily Lentivirinae, which includes human, simian, feline and bovine immunodeficiency viruses (HIV, SIV, FIV and BIV, respectively), equine infectious anaemia virus (EIAV) and the closely related caprine arthritis encephalitis virus (CAEV). Unlike HIV and other immunodeficiency viruses, VISNA infects cells of the monocyte/macrophage lineage and dendritic cells but not T lymphocytes (Gendelman et al., 1985 (Gendelman et al., , 1986 Gorrell et al., 1992; Ryan et al., 2000) . Due to the tropism for mononuclear phagocytes, lymphoid tissues are considered to be important targets for the replication of VISNA (Blacklaws et al., 1995a; Pétursson et al., 1991) . This restriction in tropism makes VISNA a unique model for understanding immunity to and pathogenesis of lentiviruses in the absence of T-cell infection in the infected host.
Cytotoxic T-lymphocytes (CTL) play an important role in immune control of both acute and chronic viral infections and are key immunological mediators of viral clearance (Harty et al., 2000; Wong & Pamer, 2003) . In lentiviral infections, control of replication of HIV and SIV has been linked strongly to robust specific CD8 + CTL although CD4 + T-lymphocyte responses and antibodies are also important (Benito et al., 2004; Heeney & Plotkin, 2006; Maecker & Maino, 2003; McMichael & Rowland-Jones, 2001 ); protection in an FIV vaccination model has been linked to T-lymphocyte responses (Flynn et al., 1996; Hosie et al., 1998; Pu et al., 1997) ; and CTL are also associated with control of virus replication in horses infected with EIAV . It would therefore be reasonable to assume that protective mechanisms in VISNA will involve CTL.
Although we have shown the presence of precursor CTL and ex vivo directly active CTL in VISNA-infected sheep previously (Bird et al., 1993; Blacklaws et al., 1994 Blacklaws et al., , 1995b ) the proteins of the virus recognized have not been determined. In this study, we have shown that all VISNA proteins except for TAT are recognized by CTL and that POL contained a cluster of epitopes in its central region (aa 612-636) . We have also shown that a DNA-prime-Modified vaccinia virus Ankara (MVA)-boost vaccination regime is successful in inducing a CTL response in sheep. Given the restricted tropism of VISNA, this new information on the epitope specificity of CD8 + CTL against VISNA is relevant to our understanding of CD8 + T-cell recognition of infected macrophages and dendritic cells in all lentiviral infections.
METHODS
Animals. Adult sheep were used: Finnish Landrace6Dorset crosses (sheep B1125, B1139, B1117, B1123, B1127 and B1129), Friesland (sheep J057 and J141) and Lleyn (sheep C139 and C175) . Sheep (B1125, B1139, J057, J141, C139 and C175) were infected with VISNA strain EV1 (Sargan et al., 1991) for .3 months before use. Finnish Landrace6Dorset crosses (B1125 and B1139 only) were given 10 5 TCID 50 virus subcutaneously; Friesland and Lleyn sheep were infected intratracheally with 10 5 and 10 3 TCID 50 VISNA, respectively. Sheep used for preparation of heterologous skin cells used in the CTL assays were BF1 (Black Face), C111 and D142 (Lleyn). Chromium release assays were used to show that heterologous skin cells did not present VISNA antigen to CTL of sheep under study (data not shown). All sheep were kept in the animal facilities of the Department of Veterinary Medicine, University of Cambridge and were used in accordance with procedures laid out in the Animals (Scientific Procedures) Act (1986) of the UK.
Viruses and antibodies. VISNA strain EV1 is the British isolate of VISNA (Sargan et al., 1991) and viral stocks were grown and titred in sheep skin cells (Bird et al., 1993) .
MVA was obtained from Professor G. Smith, Imperial College, London, UK. Recombinant MVA (rMVA) viruses expressing all VISNA genes were constructed within our laboratory using the transfer plasmid pSC11 (Chakrabarti et al., 1985) . The intermediate transfer plasmid pSC11env was a kind gift from Dr D. Rodríguez, Centro Nacional de Biotecnologia-CSIC, Madrid, Spain (Sánchez et al., 2002) . Other plasmids were constructed using PCR products from Hirt prepared DNA (gag, pol, env, vif, gag p17, gag p25 and gag p14) or from cDNA (tat and rev) of VISNA EV1-infected cells, using primers to add start and stop codons as necessary. Six overlapping fragments of the pol gene were amplified by PCR with the pol gene clone [pBluescriptSKpol1.13, pol insert sequence (GenBank accession no. EU528031) used in full-length pol rMVA] as template. Primers were as follows for individual fragments (nucleotide positions in pol are indicated in parentheses; F, forward primer; R, reverse primer; BamHI sites are underlined, start codons in bold): fragment 1 (1-608), PolF4 59-AAGGATCCACCATGCATACAGCTGCAGGGAAA-39, PolR4 59-TGGATCCAAGCTTCAATTCCCTGAAGTCTATTAA-CAT-39; fragment 2 (538-1126), PolF5 59-AAGGATCCACCATG-AGCACTCCTATATTTTGCATC-39, PolR5 59-TGGATCCAAGCTT-TGGTCCTTCTTCCATATCTG-39; fragment 3 (1063-1677), PolF6 59-AAGGATCCACCATGGAACTACATCCAGAGAGATG-39, PolR6 59-TGGATCCAAGCTTGTATAATATGTTGGCCCCTC-39; fragment 4 (1609-2176), PolF7 59-AAGGATCCACCATGAGGGGATCAGT-AAGATGGAA-39, PolR7 59-TGGATCCAAGCTTCCCTATCATAGC-CCATTGATT-39; fragment 5 (2104-2793), PolF8 59-AAGGATCC-ACCATGGCAGGACAAGTAAAGAAGAT-39, PolR8 59-TGGATCC-AAGCTTTTCTGCTATAAATGCTGGTCC-39; fragment 6 (2719-3267), PolF9 59-AAGGATCCACCATGACAACTATGAAGTGGTA-TGC-39, PolR9 59-TGGATCCAAGCTTAGGCCCTATCTCCCTAT-TT-39. PCR products were cloned into a cloning vector for sequencing, then the relevant insert was subcloned into the SmaI site of pSC11 and the correct orientation was confirmed by restriction enzyme digestion and sequencing. Recombinant viruses were made as described previously (Sánchez et al., 2002) , routinely grown in QT35 cells (fibrosarcoma cells from Japanese quail, ECACC reference no. 93120832) and the titre determined by plaque assay (p.f.u.) using bgalactosidase staining for recombinant virus plaques. Expression of VISNA genes was confirmed by Western blotting and/or RT-PCR (data not shown). rMVA expressing full-length gag was called MVAgag, full-length pol MVApol, env MVAenv, tat MVAtat, rev MVArev, vif MVAvif, and gag subfragments: matrix p17 MVAp17, capsid p25 MVAp25 and nucleoprotein p14 MVAp14. The rMVAs expressing fragments of pol were called MVApolfragment1-6. A rMVA was also generated using pSC11 alone (MVApSC11) to act as a control virus expressing b-galactosidase.
Monoclonal antibody (mAb) VPM19 (Hopkins & Dutia, 1990 ), specific for ovine major histocompatibility complex (MHC) class I antigens (mouse IgG1), was grown and purified in our laboratory, and purified mAb IL-A88 (Toye et al., 1990) , specific for bovine MHC class I antigens (mouse IgG2a), was kindly provided by Dr S. Ellis (Institute for Animal Health, Compton, UK).
Generation of DNA vaccines. Using pBluescriptSKpol1.13 plasmid DNA as template, full-length pol and pol gene fragment 4 (positions 1609-2175 in pol) were amplified by PCR using the Expand Long Template PCR System kit or Pwo DNA polymerase (both by Roche), respectively. The amplified full-length VISNA pol gene and pol fragment 4 were inserted into the BamHI site of pcDNA3.1his/V5 (Invitrogen) and called pcDNA3.1polD and pcDNA3.1polfrag4, respectively. To generate a full-length POL fusion protein expressing the V5 tag for testing expression of the protein, the stop codon in the full-length pol gene was deleted by XbaI digestion using an internal pol gene XbaI site and the pcDNA3.1/His-V5 multiple cloning XbaI site, causing the deletion of a 78 bp 39 fragment of the pol gene including the stop codon. The correct construction of pcDNA3.1polD and pcDNA3.1polfrag4 was confirmed by sequencing; then plasmid DNA was used to transfect nearly confluent QT35 monolayers using Fugene6 (Roche) in Glasgow's modified Eagle's medium (GMEM) supplemented with 2 % fetal calf serum (FCS), 10 % tryptose phosphate broth (TPB: 2 % bacto tryptose, 0.2 % bacto dextrose, 0.5 % NaCl, 0.25 % Na 2 PO 4 ), 100 U penicillin and 100 mg streptomycin ml 21 (2 %FCS/TPB/GMEM) for 48 h as per the manufacturer's directions. Expression of pol and pol fragment 4 was analysed by RT-PCR and flow cytometry using antibody specific for either the polyhistidine-tag or the V5 epitope-tag (Serotec) and then a fluorescently labelled antibody (fluorescein isothiocyanate-conjugated rabbit anti-mouse IgG; DakoCytomation) (data not shown).
Synthetic VISNA POL peptides. The predicted POL fragment 4 amino acid sequence was used to synthesize 36 overlapping 15-mer peptides (P1.1-1.35: offset by 5 aa, P1.36 offset by 4 aa) by using a 96-well Pepscan method (Cambridge Peptides). Eight overlapping 12-mer peptides, offset by 2 aa (P2.1-2.7) or 1 aa (P2.8), corresponding to POL amino acid positions 612-636 were synthesized by Mimotopes (Fig. 1 ). Peptides were dissolved in sterile 0.1 M HEPES pH 7.4 in 40 % acetonitrile to make 5 mg ml 21 stocks (this was assumed for the pepscan peptides from the usual pepscan yield) and stored at 280 uC. The peptide stocks were diluted in RPMI 1640 containing 2 mM L-glutamine, 20 mM HEPES, 100 U penicillin and 100 mg streptomycin ml 21 and 50 mM 2-mercapoethanol with 10 % FCS (10 % RPMI) to a final concentration of 20 mg ml 21 for each peptide before use (pools of peptides were used at 20 mg ml 21 for each peptide).
Skin cell lines. Skin cell lines were derived from skin biopsies as described previously (Bird et al., 1993 ) before sheep were infected or immunized. Cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 2 mM L-glutamine, 100 U penicillin and 100 mg streptomycin ml 21 and 10 % FCS (10 % DMEM).
Preparation of sheep peripheral blood mononuclear cells (PBMCs) as CTL effectors. Preparation of CTL effectors from PBMCs was performed as described previously by stimulation for 14 days on autologous VISNA-infected skin cell fibroblasts in the presence of interleukin (IL)-2 . Viable cells from cultures were adjusted to the required concentrations in 10 % RPMI 1640 for use as effectors in CTL assays.
CTL chromium release assay. Sheep skin cells, either autologous or heterologous, were used as target cells to present VISNA antigens, as in Blacklaws et al. (1994 Cr in 10 % DMEM overnight. rMVA-infected targets were washed three times, then either mock infected or infected with 10 p.f.u. rMVA per cell for 4 h in 2 % DMEM, washed once more and used. Targets loaded with peptides were washed four times and incubated with peptides for 1 h in half the final reaction volume at double the final concentration (20 mg ml 21 10 % RPMI 1640) then effectors were added to give the final reaction volume and peptide at 10 mg ml 21 . Triplicates of two dilutions of lymphocyte effectors were added to target cells to give a final volume of 100 ml per well. Effectors and targets were incubated for 8-16 h at 37 uC then 40 ml supernatant was mixed with 120 ml Optiphase Hisafe 3 (Perkin-Elmer) in 96-well ELISA plates and counted by scintillation counting (1450 Microbeta counter; Wallac). Spontaneous and maximal 51 Cr release was determined by incubating target cells in medium or 1 % Triton X-100, respectively. Specific chromium release, i.e. lysis of cells was calculated by the formula: % specific lysis5[(experimental release2 spontaneous release)/(maximal release2spontaneous release)]6100. The mean±SD of triplicate wells is shown in the graphs and tables.
Inhibition of antigen presentation by MHC class I mAbs. Anti-MHC class I antibody inhibition of antigen presentation was assessed as follows: skin cell targets were prepared as described above. One hour before the addition of effectors, targets were incubated with anti-ovine or -bovine MHC class I or a non-specific mouse IgG1 mAb to give a final concentration of 10 mg ml 21 in 100 ml after the addition of effectors. Finally, effectors were incubated with targets for 12 h.
Immunization of animals with plasmid DNA and rMVA. Plasmid DNA of pcDNA3.1polfrag4 and pcDNA3.1polD was prepared using a Plasmid Preparation kit (Sigma-Aldrich) as per the manufacturer's directions. Finally, DNA was quantified using the PicoGreen DNA quantification kit (Invitrogen) as per the manufacturer's instructions. For immunization, DNA/polyethylenimine (PEI, 25 kDa branched; Sigma-Aldrich, cat. no. 40 872-7) complexes were prepared at ratios of 1 : 10 DNA phosphate to PEI nitrogen (i.e. 1 mg DNA : 1.29 mg PEI) in water for injection. The complexes were allowed to stand for at least 20 min before use. Animals were given 400 mg plasmid by injection, half given intramuscularly and half subcutaneously. rMVAs were purified using sucrose density-gradient centrifugation (Madalinski et al., 1977) . Animals were immunized with 3610 8 p.f.u. rMVA subcutaneously. Animals received injections of DNA twice then rMVA once at 3 weekly intervals. Sheep B1117 and B1123 were immunized with VISNA pol fragment 4; sheep B1127 and B1129 with whole length pol (minus 78 bp at the C-terminal end). PBMCs were tested for precursor CTL activity before immunization, 3 weeks after the second DNA immunization and 3 or 6 weeks after the rMVA boost.
RESULTS
Mapping VISNA CTL epitopes in different breeds of sheep VISNA-infected sheep from three breeds were used to determine which VISNA antigens contained CTL epitopes. All sheep had CTL that could recognize VISNA antigens expressed from rMVA. Both Finnish Landrace6Dorset cross sheep (B1125 and B1139, Table 1) recognized the pol gene product. The two Friesland sheep used displayed The 25 aa region of POL containing the CTL epitopes was aligned with the same region in other small ruminant lentivirus isolates (SRLV). Sequences used were a USA isolate of CAEV (USA CAEV; GenBank accession no. M33677); Icelandic strains of VISNA including 1514, its molecular clone derivatives LV1-1KS1 and 2 and KV1772, the neuropathogenic Icelandic molecular clone (GenBank accession nos M10608, M60609, M60610 and L06906); North American VISNA molecular clone 85/34 and a SRLV isolate from Swiss goat's milk (GenBank accession nos AY101611 and AY445885); a Norwegian CAEV isolate (GenBank accession no. AF322109); the South African VISNA isolate, SA-OMVV (GenBank accession no. M31646) and the Portuguese VISNA isolate, P1OLV (GenBank accession no. AF479638). The consensus sequence is shown with " representing agreement with consensus and differences as indicated. Nonconservative changes are shown by a grey block. One of the conserved aspartic acid (D) residues necessary for activity in E. coli RNaseH is indicated in bold type (Kanaya et al., 1990 (Fig. 2a, b) . Other rMVA pol fragment (MVApolfragment1-3 and 5-6)-infected cells showed background levels of lysis. These levels of lysis were as high as lysis of target cells infected by VISNA itself (data not shown).
A series of 36 overlapping peptides was synthesized using the predicted amino acid sequence of POL fragment 4. These were made into six pools of six peptides each. CTL effectors from both sheep B1125 and B1139 caused the greatest specific lysis of peptide-pool-3-sensitized targets, whilst the specific 51 Cr release of other peptide pools was much lower and similar to that of negative controls (Fig. 2c , VISNA CTL epitope mapping d). This indicated that peptide pool 3 contained a peptide(s) presented to CTL from sheep B1125 and B1139. Skin cell targets from sheep B1125 were also able to present peptide pool 3 peptides to CTL effectors from sheep B1139 with levels of target cell lysis similar to those in CTL assays with autologous CTL effectors and targets (Fig. 3) .
The individual peptides from peptide pool 3 were used to sensitize targets. Three consecutive peptides (P1.16-18) spanning a 25 aa region (DSRYAFEFMIRNWDEEVIKN-PIQAR) located at positions 612-636 in the whole length POL antigen were presented to CTL derived from sheep B1125 and B1139 (Fig. 4a, b) . To map the CTL epitope(s) in this 25 aa region of VISNA POL, eight overlapping 12 aa peptides, offset by 2 aa (P2.1-2.7) or 1 aa (P2.8) were synthesized ( Fig. 1a) and individually loaded into targets for CTL assays. The longest peptides isolated from cattle MHC class I are 12 aa in length (Gaddum et al., 1996) . Four peptides, P2.1 (DSRYAFEFMIRN), P2.5 (MIRNWDEEVIKN), P2.7 (WDEEVIKNPIQA) and P2.8 (DEEVIKNPIQAR) induced the highest and similar levels of lysis of targets by CTL (Fig. 4c, d ). Peptides P2.2, P2.4 and P2.6 caused approximately half the level of lysis by CTL as P2.1, P2.5, P2.7 and P2.8 (Fig. 4c, d ). Peptide P2.3 was not presented to the CTL effectors used. None of the peptides sensitized heterologous target cells to lysis by sheep CTL (Fig. 4) . The Cterminal 15-mer peptide from POL, P1.36, was used as a control peptide on targets and did not sensitize target cells to lysis (Fig. 4c, d) . Comparison of the four most highly active 12-mer peptides showed that P2.1 and P2.5 shared 4 aa, P2.5 and P2.7 shared 8 aa, P2.5 and P2.8 shared 7 aa, and P2.7 and P2.8 shared 11 aa. This, with the pattern of recognition of the intervening peptides (especially peptide P2.6, which was not presented efficiently), suggests that a cluster of three or more epitopes are present in this 25 aa region of POL: within DSRYAFEFMIRN (612-623), and DEEVIKNPIQA (625-635) (Fig. 1a) .
Three of the epitope-containing peptides (P2.1, P2.5 and P2.8) were diluted serially and used to load target cells. The assay with B1139 effectors at one of the effector : target ratios used is shown (Fig. 5) . Peptide concentrations from 0.01 to 10 mg ml 21 (~6.5-6500 nM) sensitized target cells for lysis by CTL. They were not effective at 1 ng ml 21 (~0.65 nM) when levels of lysis were similar to those for control peptide (P1.36)-loaded targets (Fig. 5) .
MHC class I presentation of peptides
To confirm that cytotoxic activity was mediated by MHC class I-restricted CTL (CD8 + CTL), CTL assays were carried out in the presence of anti-MHC class I mAb using rMVA-infected targets or targets loaded with a pool of the three positive 15-mer peptides (P1.16-1.18). Cytotoxic activity specific for both MVApolfragment4-infected or peptide-loaded target cells was blocked by mAb specific for either ovine or bovine (cross-reactive with ovine) MHC class I antigen but not the control mouse IgG1 (B1139 effectors, Fig. 6 ). Consistent results were obtained using effectors from sheep B1125 (data not shown). The CTL epitopes in POL (recognized by B1125 and B1139) were therefore presented to CTL by MHC class I molecules. Induction of specific CTL activity by DNA vaccination of sheep Four Finnish Landrace cross sheep (B1117, B1123, B1127 and B1129) were shown to share MHC class I alleles with B1125 and B1139 by CTL assay using B1125 and B1139 CTL effectors against VISNA-infected skin cells of the four sheep (data not shown). Sheep were immunized with either pol fragment 4 (B1117 and B1123) or pol (B1127 and B1129) by a DNA-prime-boost method. CTL isolated from all four sheep before the start of immunization did not recognize VISNA, pol or pol fragment 4 (data not shown). Three weeks after the second prime with DNA, precursor CTL with weak activity specific for VISNA pol fragment 4 was detectable in two of the immunized sheep (B1117 and B1129) (data not shown). However, VISNA-infected targets were not recognized by CTL in these assays. By 3 weeks after the rMVA boost all four sheep showed weak precursor CTL activity against pol or pol fragment 4, with three of four of the sheep also showing activity against VISNA-infected targets (data not shown). By 6 weeks after the rMVA boost, all four sheep showed precursor CTL activity specific for VISNA, pol or pol fragment 4 in their PBMCs (Fig. 7) .
DISCUSSION
In this study, we have been able to map CTL epitopes in VISNA antigens and to show that when a small region of antigen containing a cluster of CTL epitopes was used in DNA-prime-boost vaccinations of sheep, CTL were stimulated. This is the first report to show which VISNA antigens were recognized by CD8
+ CTL from VISNAinfected sheep. Cellular immune responses including CD8 + T-cell responses have been shown previously to develop after VISNA infection but little work has been carried out on antigen specificity (Bird et al., 1993; Blacklaws et al., 1994; Griffin et al., 1978; Larsen et al., 1982; Reyburn et al., 1992; Sihvonen, 1981; Torsteinsdó ttir et al., 1992) . Fibroblasts from individual sheep were able to present different VISNA antigens to CTL, probably because of varying MHC class I backgrounds. TAT was the only protein that did not contain a CTL epitope. VISNA tat has recently been compared with HIV-1 vpr because of the lack of a TAR element in the VISNA LTR and weak upregulation of viral promoter activity in the presence of TAT (Villet et al., 2003) . HIV VPR and TAT both contain CTL epitopes. With only six sheep used here it is likely that VISNA TAT will also prove to contain epitopes when more sheep are studied rather than there being an inherent lack of processing or immunogenicity of this protein. With bluetongue virus, it has been found that there is considerable diversity in the CTL recognition patterns in sheep tested (Janardhana et al., 1999) .
The specific lysis of targets was variable in some of the different experiments shown here. This variability was independent of the animal analysed, or the types (infected or peptide loaded) of targets used in experiments and we could not identify the cause. The majority of assays were incubated for 16 h, although in attempts to reduce background levels, assays of less than 16 h were also performed. These reduced overall specific lysis as well as background levels. We used the same sources of medium, FCS and IL-2 throughout. We also kept skin cell targets between passage 6 and 20, although we have not noted differences in the ability to kill different ages of skin cells before. One possible explanation we have is that the infection of the fibroblast feeders used to activate CTL cultures may have varied with different stocks of VISNA. VISNA causes a slow spreading infection of fibroblasts throughout the culture period and if this varied it may have affected the activity of the CTL generated.
Cytotoxic activity may be mediated by CD8 + CTL, CD4 + CTL or NK cells. However, it has been shown that a major proportion of cell-mediated cytotoxicity is performed by MHC class I-restricted CD8 + T cells in different viral infections (Harty et al., 2000) . Using the culture method employed here or macrophages as antigen presenting cells, it has been shown previously that VISNA-specific CTL activity is mediated by CD8 + T lymphocytes Lee et al., 1994) . POL (expressed by MVA or as peptides)-specific cytotoxicity reported here was inhibited by mAb specific for MHC class I antigen. There was also no evidence that the sheep skin cells used as targets express MHC class II (by flow cytometry, data not shown). This indicates that VISNA POL epitopes were presented in a MHC class I-restricted manner to CTL.
In a group of highly related sheep sharing MHC class I antigens, several epitopes within POL were shown to cluster in a short 25 aa region of the protein associated with RNaseH activity. We have not mapped these epitopes to presentation by particular class I molecules and so they P2.5 and P2.8) and used in assays with B1139 effectors at an effector : target ratio of 20 : 1. MVApolfragment4 (polf4)-infected targets were used as a positive control, and MVApSC11-infected targets (pSC11) and targets sensitized with an unrecognized peptide, P1.36, were used as negative controls. Heterologous skin cell targets pulsed with P2.1, P2.5 and P2.8 did not show levels of specific lysis greater than the negative controls with autologous skin cells (data not shown).
may be presented by different class I molecules. The first amino acid (D) of this region is one of the conserved aspartic acid residues necessary for RNaseH activity in Escherichia coli (Kanaya et al., 1990, Fig. 1 ) and three of the first 4 aa are conserved amongst all the lentiviruses. This 25 aa region of POL is well conserved within the small ruminant lentiviruses, with common substitutions being conservative (Fig. 1b) .
CTL epitopes have been mapped in all lentiviruses except CAEV and BIV. HIV and SIV have the largest epitope database (www.hiv.lanl.gov/content/index) where epitopes are also known in the context of different MHC class Ipresenting molecules. Epitopes are often clustered on protein sequences in conserved regions and this is thought to be caused by natural antigen processing on the proteasome, presentation and the ability to screen crossreacting peptide sequences within individuals (LucchiariHartz et al., 2003; Walker & Korber, 2001) . There is limited knowledge of EIAV epitopes but a cluster of epitopes is present in the GAG matrix and capsid regions (Chung et al., 2004) . There is also evidence of epitope clustering in other virus families, e.g. hepatitis B virus (Chisari & Ferrari, 1995) and hepatitis C virus (Rehermann, 2000; Wong et al., 2001) . Therefore, the presence of a cluster of epitopes in a conserved region of a protein as we see here is characteristic of antiviral responses in diverse species.
We have not defined optimal length peptides here but have used 12-mer peptides. One optimal 9-mer (ISIDQILEA) epitope has been defined in a conserved region of bovine leukaemia virus (BLV) gp51 in merino sheep (Hislop et al., 1998) . Several optimal epitope peptides have been defined with corresponding BoLA presentation molecules in cattle. These vary from 9 to 12-mer peptides with 9 or 11-mer peptides being most commonly seen (Gaddum et al., 1996; Graham et al., 2008; Sinnathamby et al., 2004) . Similarly, the length of CD8 + CTL epitopes in humans varies from 8 to 11-mers depending on the specific MHC class I allelebinding groove. Thus, 12-mer peptides gave a reasonable chance of containing epitopes for MHC class I presentation in sheep, although the sensitivity of the assay may have been reduced by using suboptimal peptide lengths.
Peptides that caused sensitization of targets to CTL were active to~6.5 nM. EIAV epitopes for CTL in gag have been classified as having high functional avidity if optimal peptides sensitize targets at ,11 nM or low functional avidity if .1000 nM is required, with reactivity to a highfunctional-avidity epitope correlating with increased control of virus [more days since the last clinical episode; Chung et al. (2005) ]. As EIAV is macrophage-tropic this is particularly relevant for VISNA. The peptides used here were not optimal and their binding range was of high avidity, suggesting they may be of functional use in viral control.
By CD8
+ T-cell depletion and an acute infection model, we have not been able to show a role for CTL in control of VISNA infection (Eriksson et al., 1999) ; however, the slow rate of virus replication and residual CD8 + T-lymphocyte populations in tissues during these experiments may mean that there was sufficient CTL activity remaining to control VISNA replication. The VISNA-infected sheep used here to map the CTL epitopes in POL had no clinical signs of VISNA infection during these experiments or at postmortem, suggesting they were controlling virus replication. It is in the late stages of VISNA disease that increased virus load and antigen are seen (Brodie et al., 1992; McNeilly et al., 2007; Narayan & Clements, 1989) . With immunodeficiency viruses, control of virus load has been linked to the quality and strength of the antiviral CTL response (Heeney & Plotkin, 2006) .
The results of CTL assays with PBMCs isolated from DNAprime-rMVA-boost immunized sheep indicated that subunit vaccines were capable of inducing the same anti-VISNA CTL specificity as in VISNA-infected sheep. There was weak CTL activity induced after DNA priming in a subset of sheep (data not shown) and this reactivity increased with the MVA boost. This is the first study to show induction of CTL by a prime-boost method in sheep. It is likely that the full-length pol gene and pol fragment 4 constructs also contained T helper (MHC class-II-presented) epitopes, which may have induced CD4
+ T-lymphocyte responses, which then help in the induction of the CD8 + lymphocyte responses. It will be interesting to try induction of CTL reactivity by minimal epitopes with this method.
Advantages of DNA-prime and recombinant virus-boost immunization strategies are well recognized. A popular prime-boost regimen is that of DNA priming followed by recombinant poxvirus or adenovirus boosting (Amara et al., 2002; McDermott et al., 2005; Wang et al., 2005) . Such prime-boost regimens are able to raise cellular immunity, and this has produced encouraging results with the longsought malaria vaccine (Gilbert et al., 2006; McConkey et al., 2003) and in models of HIV infection (Heeney & Plotkin, 2006) . The levels of specific CTL activity in immunized sheep may be improved further if optimal immunization dose, adjuvant, route and interval are investigated (Babiuk et al., 2003; Chaplin et al., 1999; De Rose et al., 2002; Gurunathan et al., 2000; Scheerlinck et al., 2004; Watkins et al., 2005) . Immunization to induce CTL activity can provide protection from retrovirus infection in sheep: immunization with an optimal CTL peptide within BLV gp51 protected sheep from challenge with BLV; however, this protection was not total as there was late isolation of BLV from immunized sheep (Mateo et al., 2001 ).
In conclusion, we describe the first, to our knowledge, systematic screening for CD8 + CTL epitopes in VISNA antigens. Results showed that all antigens of VISNA acted as CTL targets except for TAT in this study using a limited number of sheep. POL antigen was recognized by CTL from sheep sharing MHC class I alleles, and one cluster of at least three CTL epitopes was identified. Immunization by DNA-prime-boost using rMVA induced specific CTL and this will allow further investigation of the role of CD8 + T lymphocytes in control of this macrophage-and dendritic-cell-tropic lentivirus infection. 
